Sep 8, 2025 | Press Releases
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2 With ANKTIVA, the first FDA-approved...
Aug 26, 2025 | Press Releases
First chemotherapy-free trial combining ANKTIVA, an IL-15 agonist, natural killer (NK) cell therapy, and Optune immune-stimulating device for patients with glioblastoma (GBM) brain tumors who have failed current standard of care Encouraging early results observed to...
Aug 19, 2025 | Press Releases
Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that can result in chronic conditions and disability2 Long COVID remains a significant public health challenge with no currently available established...
Aug 13, 2025 | Press Releases
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete response at six months with CD19 CAR-NK in combination with rituximab First...
Aug 11, 2025 | Press Releases
CULVER CITY, Calif., August 11, 2025 – ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region...
Aug 5, 2025 | Press Releases
Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of approximately $43 million. ANKTIVA® Unit Growth Since J-code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash...
